zinc finger protein 799Genealiases: HIT-40 · HIT40 · ZNF842
Q-omics provides the consensus-scored ZNF799 profile across patient tissues and cancer cell-line models. ZNF799 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF799 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ZNF799 RNA expression shows 20,534 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ZNF799 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF799 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF799 survival associations across molecular data types. ZNF799 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF799 RNA expression–survival associations across cancer types. High ZNF799 expression shows unfavorable associations in LGG and ACC, but favorable associations in KIRC, HNSC, UCEC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF799 RNA expression.
This table summarizes ZNF799 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF799. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF799 shows lower tumor expression in KICH and LUAD and higher tumor expression in LIHC, STAD, BLCA and READ. The KICH box plot shows higher ZNF799 RNA expression in normal versus tumor tissue (log2 FC = −0.828, t-test p < 0.001).
This table shows molecular features associated with ZNF799 in patient tissues and cancer cell lines. In patient samples, ZNF799 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF799 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
